Active Clinical Trials

Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma

By April 24, 2017 No Comments


Advanced Malignant Pleural Mesothelioma

Estimated Enrollment: 26

Age Group: 18 Years to 75 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: INCANOGAR2012-JA3

Study First Received: April 18, 2012

Last Updated: March 1, 2017

Estimated Primary Completion Date: December 2017


Primary Outcome Measures:

Evaluate adverse effects to 250 mg/m2 infusion gemcitabine|Progression Free Survival|overall survival

Sponsors and Collaborators:

Instituto Nacional de Cancerologia de Mexico|National Council of Science and Technology, Mexico

Website Link:

Leave a Reply

Call Now ButtonCall Now